ClinConnect ClinConnect Logo
Search / Trial NCT06874634

Albumin Infusion Targets on Mortality in Patients With Abdominal Sepsis

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Mar 7, 2025

Trial Information

Current as of April 23, 2025

Completed

Keywords

Sepsis, Abdominal Infection

ClinConnect Summary

Research Background Introduction to Sepsis and Abdominal Sepsis Sepsis is a life-threatening condition characterized by organ dysfunction due to a dysregulated immune response to infection. Abdominal sepsis, originating from intra-abdominal infections, is particularly challenging due to its high morbidity and mortality rates. The mortality rate for abdominal sepsis ranges from 7.6% to 36.0%, and it can reach up to 50% if it progresses to septic shock. The presence of hypoalbuminemia further complicates the clinical course and prognosis of sepsis patients.

Role of Albumin in Sepsis Albumin ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients admitted to the Intensive Care Department of Southern Hospital of Southern Medical University from September 2017 to June 2022;
  • Age ≥ 18 years old;
  • Meeting the diagnostic criteria for abdominal infection;
  • Patients who meet the diagnostic criteria for sepsis/septic shock;
  • Complicated with hypoalbuminemia, i.e. plasma albumin\<30g/L after admission;
  • Human serum albumin injection was infused within 24 hours after check-in into the ICU.
  • Exclusion Criteria:
  • Pregnant or lactating women
  • Patients who have not been able to obtain relevant diagnosis and treatment information after ICU check-in
  • Patients who repeatedly stay in the ICU
  • ICU hospitalization time is less than 24 hours
  • Pathological conditions that require albumin treatment in clinical practice (cirrhosis with ascites, post liver transplantation, intestinal malabsorption syndrome, nephrotic syndrome, burns);

About Nanfang Hospital, Southern Medical University

Nanfang Hospital, affiliated with Southern Medical University, is a leading medical institution in China renowned for its comprehensive clinical services and commitment to advancing healthcare through research and education. As a clinical trial sponsor, Nanfang Hospital leverages its state-of-the-art facilities and a multidisciplinary team of expert researchers to conduct innovative studies aimed at improving patient outcomes and contributing to the global medical community. The hospital's focus on ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and scientific rigor.

Locations

Guangzhou, Guangdong, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported